Cabozantinib S-malate Patent Expiration
Cabozantinib S-Malate is used for treating advanced renal cell carcinoma, differentiated thyroid cancer, and hepatocellular carcinoma. It was first introduced by Exelixis Inc
Cabozantinib S-malate Patents
Given below is the list of patents protecting Cabozantinib S-malate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cabometyx | US10034873 | C-met modulator pharmaceutical compositions | Jul 18, 2031 | Exelixis Inc |
| Cabometyx | US10039757 | C-Met modulator pharmaceutical compositions | Jul 18, 2031 | Exelixis Inc |
| Cabometyx | US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cabometyx | US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cabometyx | US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cabometyx | US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | Apr 17, 2037 | Exelixis Inc |
| Cabometyx | US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis Inc |
| Cabometyx | US7579473 | c-Met modulators and methods of use | Aug 14, 2026 | Exelixis Inc |
| Cabometyx | US8497284 | C-met modulators and method of use | Sep 24, 2024 | Exelixis Inc |
| Cabometyx | US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | Oct 08, 2030 | Exelixis Inc |
| Cabometyx | US9724342 | C-met modulator pharmaceutical compositions | Jul 09, 2033 | Exelixis Inc |
| Cometriq | US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cometriq | US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cometriq | US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cometriq | US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis |
| Cometriq | US7579473 | c-Met modulators and methods of use | Aug 14, 2026 | Exelixis |
| Cometriq | US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | Oct 08, 2030 | Exelixis |
| Cometriq | US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis |